DE60330390D1 - G-csf zur behandlung von amyotropher lateralsklerose - Google Patents
G-csf zur behandlung von amyotropher lateralskleroseInfo
- Publication number
- DE60330390D1 DE60330390D1 DE60330390T DE60330390T DE60330390D1 DE 60330390 D1 DE60330390 D1 DE 60330390D1 DE 60330390 T DE60330390 T DE 60330390T DE 60330390 T DE60330390 T DE 60330390T DE 60330390 D1 DE60330390 D1 DE 60330390D1
- Authority
- DE
- Germany
- Prior art keywords
- amyotropher
- csf
- treatment
- lateral sclerosis
- gcsf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title abstract 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title abstract 4
- 201000010901 lateral sclerosis Diseases 0.000 title 1
- 208000005264 motor neuron disease Diseases 0.000 title 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108010002386 Interleukin-3 Proteins 0.000 abstract 1
- 102100039064 Interleukin-3 Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101150099872 Stat gene Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33175502A | 2002-12-31 | 2002-12-31 | |
US10/659,295 US7785601B2 (en) | 2002-12-31 | 2003-09-11 | Methods of treating neurological conditions with hematopoietic growth factors |
PCT/IB2003/006446 WO2004058287A2 (en) | 2002-12-31 | 2003-12-31 | Methods of treating neurological conditions with hematopoeitic growth factors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60330390D1 true DE60330390D1 (de) | 2010-01-14 |
Family
ID=32710846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60330390T Expired - Lifetime DE60330390D1 (de) | 2002-12-31 | 2003-12-31 | G-csf zur behandlung von amyotropher lateralsklerose |
Country Status (8)
Country | Link |
---|---|
US (8) | US7785601B2 (de) |
EP (2) | EP2186525A3 (de) |
JP (2) | JP4733521B2 (de) |
CN (3) | CN100558397C (de) |
AT (1) | ATE450268T1 (de) |
AU (1) | AU2009201467A1 (de) |
DE (1) | DE60330390D1 (de) |
RU (1) | RU2008146718A (de) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1019082B2 (de) * | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen |
CA2492542A1 (en) * | 2002-07-30 | 2004-02-05 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US7695723B2 (en) * | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
WO2004058287A2 (en) * | 2002-12-31 | 2004-07-15 | Axaron Bioscience Ag | Methods of treating neurological conditions with hematopoeitic growth factors |
WO2004106369A2 (en) | 2003-06-02 | 2004-12-09 | Evolutec Limited | Complement inhibitors from ticks |
CA2586365A1 (en) * | 2004-11-05 | 2006-05-26 | Northwestern University | Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
US20060257943A1 (en) * | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
WO2007019522A2 (en) * | 2005-08-04 | 2007-02-15 | Carlos Lopez | Reversal of adult onset disorders with granulocyte-colony stimulating factors |
BRPI0614851A2 (pt) * | 2005-08-19 | 2011-04-19 | Commw Scient Ind Res Org | luciferases de arachnocampa |
GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
US9770485B2 (en) * | 2006-02-21 | 2017-09-26 | Academia Sinica | Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF |
US20070196279A1 (en) * | 2006-02-21 | 2007-08-23 | Shen Che-Kun J | Methods for treating progressive neurodegenerative disorders |
WO2007105305A1 (ja) * | 2006-03-14 | 2007-09-20 | Japan Tobacco Inc. | 新規なβ-ガラクトシド-α2,6-シアル酸転移酵素、それをコードする遺伝子およびその製造方法 |
JP5153114B2 (ja) * | 2006-10-12 | 2013-02-27 | 知宏 千葉 | 新規のアルツハイマー病検出方法 |
KR100812274B1 (ko) * | 2006-10-30 | 2008-03-13 | 한양대학교 산학협력단 | G-csf를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제 |
US20100266528A1 (en) * | 2006-11-17 | 2010-10-21 | Biogen Idec Ma Inc. | Systemic Administration of Colony Stimulating Factors to Treat Amyloid Associated Disorders |
CN101573447A (zh) * | 2006-12-29 | 2009-11-04 | 赢创德固赛有限责任公司 | 具有降低的产物抑制作用的甲硫氨酸合酶 |
US7618938B2 (en) * | 2007-02-07 | 2009-11-17 | Academia Sinica | Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly |
US7723302B2 (en) * | 2007-05-01 | 2010-05-25 | Florida Atlantic University | Method of treating Parkinson's disease |
JP4927774B2 (ja) * | 2007-10-12 | 2012-05-09 | サントリーホールディングス株式会社 | Udp−グルクロン酸転移酵素およびそれをコードするポリヌクレオチド |
WO2009055454A2 (en) * | 2007-10-22 | 2009-04-30 | University Of Florida Research Foundation, Inc. | Xylan-utilization regulon for efficient bioprocessing of hemicellulose and uses thereof |
TW200948964A (en) * | 2008-04-17 | 2009-12-01 | Novozymes As | Laccase variants |
US9132168B2 (en) * | 2008-08-05 | 2015-09-15 | University Of South Florida | Methods of treating cognitive impairment |
CA2733126A1 (en) * | 2008-08-05 | 2010-02-11 | University Of South Florida | Methods of treating cognitive impairment |
CA2736230C (en) * | 2008-09-04 | 2021-06-29 | Abt Holding Company | Use of stem cells to prevent neuronal dieback |
US9057051B2 (en) | 2008-10-31 | 2015-06-16 | Katholieke Universiteit Leuven | Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells |
CN102316891A (zh) * | 2009-02-17 | 2012-01-11 | 森格尼斯生物科学有限两合公司 | G-csf用于延长卒中溶栓治疗的治疗时间窗的用途 |
WO2011011500A1 (en) * | 2009-07-21 | 2011-01-27 | Abt Holding Company | Use of stem cells to reduce leukocyte extravasation |
US20110020292A1 (en) * | 2009-07-21 | 2011-01-27 | Abt Holding Company | Use of Stem Cells to Reduce Leukocyte Extravasation |
US9494605B2 (en) | 2009-11-20 | 2016-11-15 | Pharnext | Diagnostic tools for charcot-marie-tooth disease |
US8652813B2 (en) * | 2009-11-25 | 2014-02-18 | Codexis, Inc. | Recombinant Thermoascus aurantiacus β-glucosidase variants |
EP2521562B1 (de) | 2010-01-08 | 2019-09-18 | Volution Immuno Pharmaceuticals SA | Ev576 zur behandlung von virusinfektionen der atemwege |
WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US9795652B2 (en) * | 2010-02-25 | 2017-10-24 | University Of South Florida | Use of endogenous antioxidant proteins in the treatment of stroke |
CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术(上海)有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
WO2011158125A2 (en) | 2010-06-17 | 2011-12-22 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
GB201011589D0 (en) * | 2010-07-09 | 2010-08-25 | Reneuron Ltd | Therapeutic cells |
US20130261165A1 (en) * | 2010-12-16 | 2013-10-03 | The Mclean Hospital Corporation | Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death |
US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
CN102212542B (zh) * | 2011-04-11 | 2012-12-19 | 上海赛伦生物技术有限公司 | 重组马gmcsf的制备方法及相关马gmcsf核苷酸序列 |
PL2734634T3 (pl) * | 2011-07-22 | 2020-03-31 | The University Of Chicago | Igf-1 do zastosowania do leczenia migreny |
EP2737905B1 (de) | 2011-07-25 | 2019-09-11 | Generon (Shanghai) Corporation Ltd. | Verwendung eines g-csf-dimer bei der herstellung eines medikaments zur behandlung von neurodegenerativen erkrankungen |
WO2013036526A1 (en) * | 2011-09-06 | 2013-03-14 | Novozymes A/S | Glucoamylase variants and polynucleotides encoding same |
WO2013067096A2 (en) * | 2011-11-01 | 2013-05-10 | Metselex, Inc. | Prevention or attenuation of neuropathic pain and kidney injury by tauroursodeoxycholic acid |
US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
WO2013149064A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells |
CN113559281A (zh) * | 2012-07-19 | 2021-10-29 | 宾夕法尼亚州研究基金会 | 再生用于在神经系统中治疗疾病和损伤的功能性神经元 |
CN103193882B (zh) * | 2013-03-29 | 2014-11-05 | 浙江大学 | 胚胎干细胞特异性标志物GM-CSFRα及其应用 |
SG10201710638UA (en) | 2013-04-12 | 2018-01-30 | Saverio Lafrancesca | Improving organs for transplantation |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
NZ720949A (en) | 2013-12-09 | 2019-03-29 | Univ Leland Stanford Junior | Methods and compositions for treating aging-associated conditions |
WO2015185602A1 (en) * | 2014-06-04 | 2015-12-10 | Affiris Ag | Treatment and prevention of parkinson's disease (pd) |
US10039808B2 (en) * | 2014-10-22 | 2018-08-07 | Michael Chez | Method of treating or improving neurological function in a human subject |
US9925244B1 (en) | 2015-02-17 | 2018-03-27 | Michael Chez | Treatment of warts in non-immunosuppressed patients |
CN107921085B (zh) | 2015-06-15 | 2021-10-22 | 小利兰·斯坦福大学托管委员会 | 用于治疗衰老相关病症的方法和组合物 |
EP4353320A3 (de) | 2016-04-28 | 2024-05-15 | Alkahest, Inc. | Blutplasma und plasmafraktionen als therapie von tumorwachstum und -progression |
US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
IL305904A (en) | 2017-04-26 | 2023-11-01 | Alkahest Inc | Dosage regimen for the treatment of cognitive and motor impairments using blood plasma and blood plasma products |
CN108404118A (zh) * | 2017-06-14 | 2018-08-17 | 张建宁 | 人源乳凝集素亚型蛋白的新用途 |
US10863912B2 (en) | 2017-08-24 | 2020-12-15 | Myneurva Holdings, Inc. | System and method for analyzing electroencephalogram signals |
CN111565736B (zh) | 2017-10-11 | 2024-03-08 | 礼蓝美国股份有限公司 | 猪g-csf变体和其用途 |
WO2019173361A2 (en) | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
BR112021006743A2 (pt) | 2018-10-26 | 2021-07-13 | Alkahest, Inc. | uso de plasma e frações plasmáticas para melhoria de dor, cicatrização de ferida e recuperação pós-operatória |
WO2023154855A2 (en) * | 2022-02-11 | 2023-08-17 | Partner Therapeutics, Inc. | Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004548A (en) | 1985-08-23 | 1999-12-21 | Amgen, Inc. | Analogs of pluripotent granulocyte colony-stimulating factor |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5641663A (en) | 1985-11-06 | 1997-06-24 | Cangene Corporation | Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces |
ES2036530T3 (es) * | 1986-01-22 | 1993-06-01 | Chugai Seiyaku Kabushiki Kaisha | Utilizacion de un factor estimulante de las colonias granulociticas humano para preparar una composicion farmaceutica para el tratamiento de la leucemia mielogena. |
DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
WO1988002482A1 (en) | 1986-09-30 | 1988-04-07 | Obrien Richard Wyndham | Determination of particle size and electric charge |
NO176799C (no) | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid |
US5214132A (en) | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
GB2213821B (en) | 1987-12-23 | 1992-01-02 | British Bio Technology | Synthetic human granulocyte colony stimulating factor gene |
US5599690A (en) | 1988-02-01 | 1997-02-04 | Amgen Inc. | Control of norleucine incorporation into recombinant proteins |
US5021239A (en) | 1988-03-21 | 1991-06-04 | Genetics Institute, Inc. | Use of M-CSF to improve lipoprotein cholesterol profiles |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
ES2063783T3 (es) | 1988-06-03 | 1995-01-16 | Chugai Pharmaceutical Co Ltd | Factor de cristalino humano de estimulacion de colonias de granulocitos y procedimiento para su preparacion. |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5629283A (en) | 1989-08-11 | 1997-05-13 | Amrad Corporation Limited | Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
EP0439952A3 (en) | 1990-01-31 | 1992-09-09 | Sgs-Thomson Microelectronics, Inc. | Dual-port cache tag memory |
US5492534A (en) | 1990-04-02 | 1996-02-20 | Pharmetrix Corporation | Controlled release portable pump |
GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
JP2946231B2 (ja) | 1990-05-31 | 1999-09-06 | 株式会社栗本鐵工所 | 超微粉分級機 |
JPH04198134A (ja) | 1990-11-28 | 1992-07-17 | Eisai Co Ltd | 老人性痴呆症の治療・予防剤 |
DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
JP3537151B2 (ja) | 1991-12-26 | 2004-06-14 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
WO1994028919A1 (en) * | 1993-06-08 | 1994-12-22 | Ajinomoto Co., Inc. | Hematopoietic cell proliferation accelerator |
US6465616B1 (en) * | 1994-04-08 | 2002-10-15 | Bresagen Limited | Interleukin-5 antagonist |
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
US5474552A (en) | 1994-06-27 | 1995-12-12 | Cb-Carmel Biotechnology Ltd. | Implantable drug delivery pump |
DE19518505A1 (de) | 1995-05-19 | 1996-11-21 | Max Planck Gesellschaft | Verfahren zur Genexpressionsanalyse |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
CA2213906A1 (en) * | 1996-09-23 | 1998-03-23 | Dusica Maysinger | Pharmaceutical composition and method for neuron rescue in ischemic stroke |
JPH10158188A (ja) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
US5895647A (en) * | 1996-12-20 | 1999-04-20 | The United States Of America As Represented By The Secretary Of The Navy | Use of oral interleukin-6 as therapy for hemorrhagic shock |
JP3503418B2 (ja) | 1997-05-15 | 2004-03-08 | ミノルタ株式会社 | 誘導加熱定着装置 |
US20010049381A1 (en) * | 1997-06-04 | 2001-12-06 | Gpl Nil Holdings, Inc., | Pyrrolidine derivative hair growth compositions and uses |
US6093167A (en) | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
EP1019082B2 (de) | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Verwendung eines kolonie-stimulierenden faktors (csf) zum verstärken des kollateralen wachstums von kollateralen arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen |
US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
EP1080093A4 (de) | 1998-05-22 | 2002-10-28 | Smithkline Beecham Corp | G-csf-mimetika |
WO1999061446A1 (en) | 1998-05-22 | 1999-12-02 | Smithkline Beecham Corporation | G-csf mimetics |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
DE69910216T2 (de) | 1998-07-22 | 2004-02-19 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6261250B1 (en) | 1998-08-20 | 2001-07-17 | Rle Corporation | Method and apparatus for enhancing cardiovascular activity and health through rhythmic limb elevation |
US6610540B1 (en) | 1998-11-18 | 2003-08-26 | California Institute Of Technology | Low oxygen culturing of central nervous system progenitor cells |
HU228488B1 (en) | 1999-01-29 | 2013-03-28 | Amgen Inc | Gcsf conjugates |
JP2004500058A (ja) * | 1999-12-03 | 2004-01-08 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | サイトカインレセプター様ポリヌクレオチド、ポリペプチド、および抗体 |
DE10033219A1 (de) | 2000-07-07 | 2002-01-24 | Univ Heidelberg | Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF) |
IL154609A0 (en) * | 2000-09-01 | 2003-09-17 | Bioacta Ltd | Anti-angiogenic polypeptides |
ATE348883T1 (de) | 2000-09-08 | 2007-01-15 | Massachusetts Inst Technology | Zusammensetzungen und verfahren mit analogen von g-csf |
WO2002022163A1 (fr) | 2000-09-13 | 2002-03-21 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre des maladies ischemiques |
AU2002219830A1 (en) * | 2000-11-10 | 2002-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
JP3607271B2 (ja) | 2001-03-12 | 2005-01-05 | 株式会社Gbs研究所 | 神経損傷の治療薬 |
JP3763749B2 (ja) | 2001-03-28 | 2006-04-05 | 独立行政法人科学技術振興機構 | 脊髄におけるシナプス形成ニューロンを誘導する中枢神経系前駆細胞 |
AU2002316201A1 (en) * | 2001-06-07 | 2002-12-16 | Quark Biotech, Inc. | Methods of using colony stimulating factors in the treatment of tissue damage and ischemia |
FR2834898B1 (fr) | 2002-01-18 | 2005-06-10 | Didier Pourquier | Nouvelle application therapeutique du g-csf, du gm-csf et du scf |
DE10211063A1 (de) | 2002-03-13 | 2003-10-09 | Axaron Bioscience Ag | Neue Verfahren zur Detektion und Analyse von Protein-Interaktionen in vivo |
AU2003240614A1 (en) | 2002-05-10 | 2003-11-11 | Ipf Pharmaceuticals Gmbh | A method of inhibiting the emigration of cells from the intravascular compartment into tissues |
EP2105136A3 (de) * | 2002-05-17 | 2010-01-27 | Celgene Corporation | Pharmazeutische Zusammensetzungen zur Behandlung von Krebs |
CA2486141A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
CA2492542A1 (en) | 2002-07-30 | 2004-02-05 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
AU2003286611A1 (en) * | 2002-10-24 | 2004-05-13 | Sangstat Medical Corporation | Cytomodulating peptides and methods for treating neurological disorders |
US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
JP4198134B2 (ja) | 2005-04-13 | 2008-12-17 | 京セラミタ株式会社 | 給紙装置 |
EP2036571A1 (de) * | 2007-09-13 | 2009-03-18 | Sygnis Bioscience GmbH & Co. KG | Verwendung von G-CSF für die Behandlung von Schlaganfall |
-
2003
- 2003-09-11 US US10/659,295 patent/US7785601B2/en not_active Expired - Fee Related
- 2003-12-31 CN CNB2003801100755A patent/CN100558397C/zh not_active Expired - Fee Related
- 2003-12-31 CN CN2009101755154A patent/CN101926981A/zh active Pending
- 2003-12-31 CN CN200910175516A patent/CN101693107A/zh active Pending
- 2003-12-31 EP EP09011942A patent/EP2186525A3/de not_active Withdrawn
- 2003-12-31 DE DE60330390T patent/DE60330390D1/de not_active Expired - Lifetime
- 2003-12-31 JP JP2005509731A patent/JP4733521B2/ja not_active Expired - Fee Related
- 2003-12-31 AT AT03799727T patent/ATE450268T1/de not_active IP Right Cessation
- 2003-12-31 EP EP10011006A patent/EP2311483A1/de not_active Withdrawn
-
2007
- 2007-08-29 US US11/846,699 patent/US20080279814A1/en not_active Abandoned
- 2007-10-31 US US11/930,758 patent/US7884069B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/932,383 patent/US8053407B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,295 patent/US8071543B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,618 patent/US20080181865A1/en not_active Abandoned
- 2007-10-31 US US11/931,326 patent/US20080171080A1/en not_active Abandoned
-
2008
- 2008-11-26 RU RU2008146718/15A patent/RU2008146718A/ru not_active Application Discontinuation
-
2009
- 2009-04-07 AU AU2009201467A patent/AU2009201467A1/en not_active Abandoned
-
2010
- 2010-09-07 JP JP2010199712A patent/JP2010270158A/ja active Pending
-
2012
- 2012-02-02 US US13/364,381 patent/US20120231065A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080175894A1 (en) | 2008-07-24 |
CN1756556A (zh) | 2006-04-05 |
US7785601B2 (en) | 2010-08-31 |
US8053407B2 (en) | 2011-11-08 |
CN101693107A (zh) | 2010-04-14 |
ATE450268T1 (de) | 2009-12-15 |
JP2006512419A (ja) | 2006-04-13 |
US20040141946A1 (en) | 2004-07-22 |
US20080171080A1 (en) | 2008-07-17 |
JP4733521B2 (ja) | 2011-07-27 |
CN101926981A (zh) | 2010-12-29 |
EP2311483A1 (de) | 2011-04-20 |
US7884069B2 (en) | 2011-02-08 |
US20090087481A1 (en) | 2009-04-02 |
US20120231065A1 (en) | 2012-09-13 |
AU2009201467A1 (en) | 2009-05-14 |
EP2186525A2 (de) | 2010-05-19 |
US20080181865A1 (en) | 2008-07-31 |
EP2186525A3 (de) | 2011-02-09 |
CN100558397C (zh) | 2009-11-11 |
US8071543B2 (en) | 2011-12-06 |
US20080279814A1 (en) | 2008-11-13 |
RU2008146718A (ru) | 2010-06-10 |
US20080241097A1 (en) | 2008-10-02 |
JP2010270158A (ja) | 2010-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60330390D1 (de) | G-csf zur behandlung von amyotropher lateralsklerose | |
ATE170082T1 (de) | Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen | |
IL250826B (en) | Methods for treating bone cancer pain by administering a growth factor antagonist | |
DE60329756D1 (de) | Mitotische kinesin-hemmer | |
CY1108927T1 (el) | Αναστολεις μιτωτικης κινεσινης | |
DE60231439D1 (de) | Mitotische kinesinhemmer | |
DE60234278D1 (de) | Mitotische kinesin-hemmer | |
DE60222302D1 (de) | Inhibitoren von mitotischem kinesin | |
ATE192045T1 (de) | Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose | |
DE60329990D1 (de) | Mitotische kinesin-hemmer | |
PL379983A1 (pl) | Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje | |
WO2004058287A3 (en) | Methods of treating neurological conditions with hematopoeitic growth factors | |
ATE484291T1 (de) | Behandlung von neurologischen störungen mit hämatopoetischen wachstumsfaktoren | |
ATE193323T1 (de) | Verwendung einer zellulären zusammensetzung zur behandlung von menschlichen oder tierischen organismen | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
ATE453386T1 (de) | Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten | |
DE602004020221D1 (de) | Inhibitoren von mitotischem kinesin | |
ATE349544T1 (de) | Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln | |
ATE268170T1 (de) | Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz | |
WO2004043353A3 (en) | Compositions and methods for treating acute myeloid leukemia | |
DE60303296D1 (de) | Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten | |
ATE269090T1 (de) | Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv | |
ATE350034T1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
ATE535246T1 (de) | Zusammensetzung zur behandlung von erkrankungen des zentralen nervensystems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |